From: Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations
Parameter | aHR | 95% CI | p-value |
---|---|---|---|
STATCOPE Full Development Cohort Model | |||
Treatment assignment | 0.93 | 0.77–1.11 | 0.41 |
Age | 1.00 | 0.99 to 1.01 | 0.69 |
Male sex | 0.84 | 0.69–1.01 | 0.07 |
Black race | 0.66 | 0.51–0.86 | 0.002 |
BMI, kg/m2 | 0.99 | 0.97–1.00 | 0.07 |
Chronic bronchitis | 1.22 | 1.00–1.49 | 0.05 |
Supplemental oxygen use | 1.26 | 1.02–1.58 | 0.04 |
SGRQ score | 1.02 | 1.01–1.02 | <0.001 |
Inhaler usea - none (0 of 3 classes: LABA, LAMA, ICS) | 0.57 | 0.39–0.84 | 0.02 |
Inhaler usea - 1 of 3 classes | 0.96 | 0.72–1.29 | 0.10 |
Inhaler usea - 2 of 3 classes | 0.74 | 0.59–0.93 | 0.40 |
Steroid or antibiotic use for AECOPD in year prior to enrollment | 1.52 | 1.13–2.05 | 0.006 |
Hospitalized for AECOPD in year prior to enrollment | 1.13 | 0.92–1.39 | 0.25 |
Ethanol use, drinks/day | 0.99 | 0.88–1.10 | 0.79 |
FEV1, % predicted | 1.00 | 0.99–1.00 | 0.19 |
Current smoker | 0.84 | 0.66–1.05 | 0.13 |
BILIRUBIN (per log 10 increase) | 0.90 | 0.74–1.09 | 0.28 |